エピソード
-
CME credits: 0.50
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-precision-payloads-exploring-adc-directed-therapies-in-her2-mutant-and-overexpressing-lung-cancer/16609/
Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC.
In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are …=
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-to-use-prognostic-risk-scoring-and-symptom-burden-assessment-to-tailor-myelofibrosis-treatment/26504/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
エピソードを見逃しましたか？
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/how-and-when-to-manage-ruxolitinib-failure/26505/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/treatment-options-for-ruxolitinib-intolerance-or-resistance-in-myelofibrosis/26506/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/pacritinib-for-myelofibrosis-across-the-cytopenic-spectrum/26507/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-anemia/26508/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/improving-transfusion-independence-with-jak-inhibitor-therapy/26509/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
-
CME credits: 0.50
Valid until: 18-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/advancements-in-gu-cancers-key-data-from-aua-2024/24417/
Despite treatment advances in genitourinary cancers, most patients will develop relapsed disease. Thus, new treatment approaches are needed, as well as improved methods to identify patients who will derive the optimal benefit from established and emerging therapies. Real-world data provide crucial insight into practice patterns and response rates, ultimately guiding individualization of treatment selection. In this activity, expert faculty assess key findings from prostate and bladder cancer trials and explore the relevance of these data to clinical practice.
= -
CME credits: 1.50
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-by-case-optimizing-dual-immune-checkpoint-inhibitor-combination-therapies-in-advanced-driver-negative-nonsmall-cell-lung-cancer/24418/
Struggling to navigate the latest immunotherapy options for advanced NSCLC? This online CME program delves into optimizing dual immune checkpoint inhibitor therapy for patients with driver-negative advanced NSCLC. Learn how to leverage recent clinical trial data and patient characteristics to individualize treatment for the best possible outcomes, including for those with challenging brain metastases.
= -
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-the-field-of-unresectable-hcc/26329/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
-
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-supporting-first-line-durvalumabtremelimumab-in-unresectable-hcc/26330/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
-
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-supporting-first-line-atezolizumabbevacizumab-in-unresectable-hcc/26331/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
-
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/selecting-the-optimal-ici-partner-for-first-line-treatment-of-unresectable-hcc-ctla-4-vs-vegf-inhibitors/26332/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
-
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/use-of-ici-combination-regimens-in-patients-with-intermediate-stage-hcc/26333/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
-
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-first-line-ici-combination-regimens-in-patients-with-unresectable-hcc/26334/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
-
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-consult-treatment-options-for-an-unresectable-hcc-patient-who-has-esophageal-varices/26335/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
-
CME credits: 1.00
Valid until: 17-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-ici-combinations-in-patients-with-unresectable-hcc/26336/
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
- もっと表示する
